Rep. April McClain Delaney Buys Labcorp Holdings Inc. (NYSE:LH) Shares

Representative April McClain Delaney (D-Maryland) recently bought shares of Labcorp Holdings Inc. (NYSE:LH). In a filing disclosed on February 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Labcorp stock on January 28th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 1/30/2026.
• Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 1/30/2026.
• Sold $1,001 – $15,000 in shares of Trimble (NASDAQ:TRMB) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 1/28/2026.
• Sold $1,001 – $15,000 in shares of BJ’s Wholesale Club (NYSE:BJ) on 1/28/2026.
• Sold $1,001 – $15,000 in shares of Trimble (NASDAQ:TRMB) on 1/28/2026.
• Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 1/23/2026.
• Sold $1,001 – $15,000 in shares of Somnigroup International (NYSE:SGI) on 1/22/2026.
• Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 1/22/2026.
• Sold $1,001 – $15,000 in shares of Morningstar (NASDAQ:MORN) on 1/15/2026.

Labcorp Trading Up 0.7%

LH opened at $272.22 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.35 and a current ratio of 1.55. The stock’s 50 day moving average price is $261.26 and its 200-day moving average price is $267.40. Labcorp Holdings Inc. has a one year low of $209.38 and a one year high of $293.72. The stock has a market cap of $22.57 billion, a price-to-earnings ratio of 26.74, a P/E/G ratio of 1.70 and a beta of 1.03.

Labcorp Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is presently 28.29%.

Institutional Investors Weigh In On Labcorp

Hedge funds have recently made changes to their positions in the stock. Harbor Asset Planning Inc. purchased a new stake in shares of Labcorp during the second quarter valued at about $25,000. Caldwell Trust Co bought a new position in shares of Labcorp during the 2nd quarter worth approximately $25,000. Financial Gravity Companies Inc. purchased a new stake in Labcorp during the second quarter valued at approximately $26,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Labcorp during the fourth quarter valued at approximately $26,000. Finally, JPL Wealth Management LLC acquired a new stake in Labcorp in the third quarter valued at approximately $28,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Labcorp from $291.00 to $317.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Robert W. Baird set a $313.00 target price on shares of Labcorp in a research note on Wednesday, January 14th. UBS Group reduced their target price on shares of Labcorp from $325.00 to $320.00 and set a “buy” rating on the stock in a research report on Wednesday, October 29th. Weiss Ratings lowered Labcorp from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, December 29th. Finally, Mizuho increased their price objective on Labcorp from $285.00 to $320.00 and gave the stock an “outperform” rating in a research note on Friday, October 17th. Ten investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $299.77.

Insider Activity

In other news, CEO Adam H. Schechter sold 5,745 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $262.75, for a total transaction of $1,509,498.75. Following the completion of the sale, the chief executive officer owned 87,574 shares in the company, valued at approximately $23,010,068.50. This represents a 6.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.84% of the company’s stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.